| Type | Public |
| HQ | San Francisco, US |
| Founded | 1990 |
| Size (employees) | 468 (est) |
| Website | nektar.com |
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Nektar Therapeutics
Robert Chess
Chairman of the Board
Jillian Thomsen
Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth
Senior Vice President, Human Resources and Facilities Operations
Timothy Riley
Senior Vice President, Technology Assessment and Quality Assurance
Report incorrect company information
Nektar Therapeutics Office Locations
Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Huntsville, US
1112 Church Street
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Report incorrect company information
Nektar Therapeutics Financials and Metrics
Nektar Therapeutics Revenue
Nektar Therapeutics's revenue was reported to be $307.71 m in FY, 2017
| USD | |
|---|---|
Revenue (Q2, 2018) | 1.1 b |
Gross profit (Q2, 2018) | 1.1 b |
Gross profit margin (Q2, 2018), % | 98.9% |
Net income (Q2, 2018) | 875.7 m |
EBIT (Q2, 2018) | 886.9 m |
Market capitalization (14-Sep-2018) | 10.2 b |
Closing stock price (14-Sep-2018) | 59.3 |
Cash (30-Jun-2018) | 911.1 m |
Nektar Therapeutics's current market capitalization is $10.2 b.
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 60.9 m | 19.8 m | 28.5 m | 132.9 m | 108.8 m | 22.7 m | 60 m | 58.9 m | 32.8 m | 36.3 m | 24.7 m | 34.6 m | 38 m | 1.1 b |
Cost of goods sold | 12.9 m | 7.9 m | 5.1 m | 9.2 m | 8.4 m | 10.5 m | 6.8 m | 8.9 m | 7.7 m | 7 m | 6.1 m | 9 m | 6.6 m | 12.2 m |
Gross profit | 48 m | 11.9 m | 23.4 m | 123.7 m | 100.4 m | 12.1 m | 53.2 m | 50 m | 25.1 m | 29.3 m | 18.6 m | 25.6 m | 31.4 m | 1.1 b |
Gross profit Margin, % | 79% | 60% | 82% | 93% | 92% | 54% | 89% | 85% | 76% | 81% | 75% | 74% | 83% | 99% |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 65.4 m | 32.4 m | 30.7 m | 32 m | 129.5 m | 20.9 m | 18.8 m | 72.5 m | 55.7 m | 63.3 m | 23.5 m | 16.1 m | 34.8 m | 911.1 m |
Accounts Receivable | 4.6 m | 1.9 m | 3 m | 46.1 m | 2.9 m | 3.7 m | 3 m | 39.7 m | 27.8 m | 14.2 m | 1.6 m | 4.1 m | 15.6 m | 35.3 m |
Inventories | 15.1 m | 12.9 m | 14.1 m | 11.7 m | 12.5 m | 10.1 m | 10.4 m | 11.3 m | 10.3 m | 10.8 m | 13 m | 11 m | 10.7 m | 11.9 m |
Current Assets | 207.9 m | 304.8 m | 298.2 m | 324.1 m | 347.3 m | 302.2 m | 286.4 m | 344.8 m | 318.3 m | 282.5 m | 381 m | 288.2 m | 336 m | 1.9 b |
Annual
Quarterly
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q1, 2018 | Q2, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (16.5 m) | (46.2 m) | (32.6 m) | 70.6 m | 33.8 m | (52.7 m) | (8.2 m) | (19.5 m) | (48.6 m) | (43.2 m) | (63.9 m) | (95.8 m) | 875.7 m |
Depreciation and Amortization | 3 m | 2.5 m | 5.1 m | ||||||||||
Inventories | 14.1 m | 11.7 m | 441 k | 10.1 m | 10.4 m | 11.3 m | 10.3 m | 10.8 m | 13 m | 51 k | (1.2 m) | ||
Accounts Payable | 7.4 m | 5.4 m | 2.2 m | 2.8 m | 2.3 m | 2.3 m | 2.3 m | 7.1 m | 7 m | 6.5 m | 5.8 m |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.2 x |
Report incorrect company information
Nektar Therapeutics Online and Social Media Presence
772 Twitter followers
Nektar Therapeutics has 772 Twitter Followers. The number of followers has increased 3.1% month over month and increased 16% quarter over quarter
Report incorrect company information
Nektar Therapeutics News and Updates
August 08, 2018
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2018
SAN FRANCISCO, Aug. 8, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2018. Cash and investments in marketable securities at June 30, 2018 were $2.1 billion as compared to $353.2 million at December 31,...
July 30, 2018
Nektar Therapeutics Announces New Drug Application for NKTR-181 Accepted for Review by FDA
SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment of chronic low back pain in adult...
Report incorrect company information
Nektar Therapeutics Company Life and Culture
Report incorrect company information